Inotuzumab ozogamicin
Inotuzumab ozogamicin 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为ACUTE LYMPHOBLASTIC LEUKEMIA。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
20 项
全球在招研究
4 项
已进入 III/IV 期
24 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- Pfizer
- Children's Oncology Group
- Charite University, Berlin, Germany
- M.D. Anderson Cancer Center
- University of Chicago
- First Affiliated Hospital of Zhejiang University
- Institute of Hematology & Blood Diseases Hospital, China
- Alliance for Clinical Trials in Oncology
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
美国、澳大利亚、加拿大、新西兰、Puerto Rico、奥地利、比利时、Czechia、丹麦、芬兰、法国、德国
正在招募患者的 Inotuzumab ozogamicin 研究
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
III 期招募中美国澳大利亚加拿大新西兰NCT03959085International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)
III 期招募中奥地利比利时Czechia丹麦NCT07476729Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab
I 期 / II 期招募中美国NCT06287229Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia
I 期 / II 期招募中美国NCT01371630Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)
II 期招募中美国NCT04747912Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia
II 期招募中美国NCT02877303Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL
II 期招募中中国NCT06554626Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia
不适用招募中中国NCT07495631Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL
II 期招募中中国NCT06387121Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
III 期招募中美国加拿大NCT03150693Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
II 期招募中美国Puerto RicoNCT03739814A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia
III 期招募中比利时丹麦Estonia芬兰NCT04307576Inotuzumab Ozogamicin in the Treatment of MRD+ After HSCT of ALL
II 期招募中中国NCT05940961Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia
II 期招募中美国NCT05645718Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
I 期 / II 期招募中美国NCT03104491Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALL
I 期招募中美国NCT06863259Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL
不适用招募中中国NCT07493161A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL
II 期招募中奥地利比利时Czechia丹麦NCT05748171Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy
II 期招募中中国NCT06985485Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma
II 期招募中美国NCT06533748
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。